Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Lymphoma / Leukemia / Myeloma News

8th Annual Multiple Myeloma Research Foundation Chicago Awards Dinner Raises $900,000 For Next-Generation Cancer Treatments

Main Category: Lymphoma / Leukemia / Myeloma
Article Date: 24 May 2009 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions
Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

In celebration of scientific and business partnerships that have extended the lives of thousands of myeloma patients, the Eighth Annual Multiple Myeloma Research Foundation (MMRF) held its Chicago Awards Dinner on May 19th at the Four Seasons Hotel in Chicago. Legendary football coach and ESPN analyst, Lou Holtz, was joined by Mistress of Ceremonies Bonnie Hunt and keynote speaker Dr. Mark Chelsky to celebrate with over 500 Chicago corporate business leaders in the quest for a cure for the deadly blood cancer.

"The MMRF has made great strides through many successful partnerships, but until there is a cure for myeloma, there is a critical need for new treatment options. This annual dinner is a way for the Chicago business community to celebrate the tremendous progress while also preparing for the next breakthrough treatment by raising significant funds," said actor, writer, producer and talk show host Bonnie Hunt, who formerly worked as an oncology nurse at Northwestern University.

According to Kathy Giusti, Founder and Chief Executive Officer of the MMRF, and a 13-year multiple myeloma patient, "The Chicago Dinner helps us build on the momentum we've created alongside our partners to bring to market the current drug options which are now being explored in the treatment of 25 other cancers. Our focused collaborations are increasing the life expectancy for patients and reshaping the model for drug development in this country." While survival has doubled in recent years and there are new effective therapies available, multiple myeloma has one of the lowest survival rates of all cancers.

Chicago land Vice Chairs for the gala awards dinner include AON; Katie and Mark Chelsky; The Damico Family Foundation; Jane and Bob DeBaun; Allison and Brian Feltzin; Becky and Lester Knight; Connie L. Lindsey and John M. Blackburn; McNamara Purcell Foundation; Sandy and Tom Mihelcic; James Moriarity - Morgan Stanley; Ronny Mosston - Millennium: The Takeda Oncology Company; Barb and Dennis Quinn; J. Christopher Reyes - Reyes Holdings, LLC; Michael J. Sacks; Grosvenor Capital Management, L.P.; and Andrew Sawyer - Celgene Corporation.



Source
Multiple Myeloma Research Foundation


Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Haiti Appeal

Haiti Appeal Image
The severe earthquake that struck Haiti has inflicted damage and devastation on a massive scale. Please donate to the Doctors Without Borders Haiti Appeal.

PLEASE DONATE HERE


These are the most read articles from this news category for the last 6 months:
Top Article Star
What Is Multiple Myeloma? What Causes Multiple Myeloma?
25 Aug 2009
Multiple myeloma, also known as myeloma or plasma cell myeloma, is cancer of the plasma cells - a kind of white blood cell which is present in the bone marrow. Plasma cells make antibodies called immunoglobulin which help fight off infections...


CML Therapy Side Effects image CML Therapy Side Effects

Even "targeted" therapy for chronic myeloid leukemia is not without side effects. Some, like low blood counts, are serious. Hear how one patient, along with her oncologist, Dr. Neil Shah of UCLA, managed the side effects of her CML treatment...

Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

View more videos...